Software AG

  • WKN: A2GS40
  • ISIN: DE000A2GS401
  • Land: Germany

Nachricht vom 13.03.2018 | 20:06

Software AG decides to cancel treasury shares and to decrease the share capital

Software AG / Key word(s): Corporate Action
Software AG decides to cancel treasury shares and to decrease the share capital

13-March-2018 / 20:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad hoc Disclosure (Inside Information according to Article 17 MAR)

Software AG decides to cancel treasury shares and to decrease the share capital

The Management Board of Software AG (TecDAX, ISIN DE000A2GS401 / SOW) decided today to redeem 2,400,000 treasury shares which had been acquired by the company in previous years based on various buy-back authorizations and to decrease the share capital accordingly by EUR 2,400,000. This corresponds to 3.14 percent of the share capital before redemption and capital decrease. The redemption is based on the authorization of the General Assembly of Software AG of May 31, 2016

After the share capital decrease, the current share capital of Software AG of EUR 76,400,000 will amount to EUR 74,000,000 and will be divided into 74,000,000 shares with a proportional share in the share capital amounting to EUR 1.00 per share. After the redemption of 2,400,000 treasury shares, Software AG will still hold 23,761 treasury shares. This corresponds to 0.03 percent of the decreased share capital.

The redemption is expected to be completed shortly.

Darmstadt, March 13, 2018

The Management Board

Software AG, Uhlandstr. 12, 64297 Darmstadt

Person making the notification:
Frederic Freichel
Junior Manager Investor Relations

Tel: +49 6151 92 1106

13-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021